信立泰(002294.SZ)奧美沙坦酯片擬中選全國藥品集中採購
格隆匯1月19日丨信立泰(002294.SZ)發佈公告,2020年1月17日,公司參加了聯合採購辦公室(以下簡稱“聯採辦”)組織的全國藥品集中採購。公司已通過國家藥品監督管理局仿製藥質量和療效一致性評價的產品“奧美沙坦酯片”擬中選本次集採。
本次擬中選產品奧美沙坦酯片規格包裝為20mg*14片,擬中選價格9.66元/盒。供應省份包括天津、山西、遼寧、江蘇、河南、重慶、貴州、青海。
公告表示,本次奧美沙坦酯片的擬中選企業為4家,根據《全國藥品集中採購文件(GY-YD2019-2)》相關規定,全國實際中選企業為4家及以上的,各地各品種首年約定採購量為首年約定採購量計算基數的80%;本輪採購週期原則上為3年。採購週期中,醫療機構將優先使用集中採購中選藥品,並確保完成約定採購量。採購週期內若提前完成當年約定採購量,超過部分中選企業仍按中選價進行供應,直至採購週期屆滿。若公司確定中選、簽訂購銷合同並實施後,將有利於快速開拓市場,提高市場佔有率,對公司未來的業績提升產生積極的影響。目前,公司已與聯採辦簽訂《備忘錄》,有關產品的購銷合同簽訂等後續事項尚具有不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.